Asia-Pacific mycoplasma testing in clinical market is projected to register a healthy CAGR in the forecast period of 2019 to 2026. The new market report contains data for the historic year 2017, the base year of calculation is 2018 and the forecast period is 2019 to 2026.

Market Segmentation

By Products (Kits and Reagents, Instruments, Services), Technique (Microbial Culture Techniques/Direct Assay, Polymerase Chain Reaction, ELISA, DNA Staining/Indirect Assay, Enzymatic Methods, Others), Disease Area (Respiratory, Urogenital, Gastrointestinal, Cardiovascular, Musculoskeletal, Others), End User (Diagnostic Laboratories, Hospitals, Others), Country (Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Rest of Asia-Pacific)

Some of the major factors contributing to the growth of Asia-Pacific mycoplasma testing in clinical market:
? Increasing number of diseases such as cardiovascular, urogenital, gastrointestinal, respiratory and others
? Increasing awareness about health in Asia-Pacific region

Market Players

The key market players for Asia-Pacific mycoplasma testing in clinical market are listed below:

? Sartorius AG
? MERCK KGAA
? ELITechGROUP
? AB ANALITICA srl
? GOLD STANDARD DIAGNOSTICS
? OSANG Healthcare
? BioFire Diagnostics
? PromoCell GmbH
? Lonza
? Thermo Fisher Scientific Inc.
? F. Hoffmann-La Roche Ltd
? Agilent Technologies, Inc.
? Liofilchem Srl
? ZEAKON Diagnostics
? OPERON
? Bio-Rad Laboratories, Inc.
? Sacace Biotechnologies Srl
? Seegene Inc.
? others